miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides

Friday, March 31, 2017

BOULDER, CO – March 31, 2017 – miRagen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan-drug designation to miRagen’s product candidate, MRG-106, for the treatment of mycosis fungoides. Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma (“CTCL”). CTCL occurs when certain types of T-cells become cancerous and cause debilitating tumors in the skin and in other parts of the body. 

Taiga Biotechnologies raises $6 million

Thursday, March 30, 2017

The University of Colorado Anschutz Medical Campus startup is well on its way to raising a targeted $14 million. Taiga's previous capital raises included $12 million in 2015. 

CU Boulder Study: Federally-Funded Laboratories and Institutions Have a $2.6 Billion Annual Impact in Colorado

Thursday, March 23, 2017

CU Boulder Study: Federally-Funded Laboratories and Institutions Have a $2.6 Billion Annual Impact in Colorado  

New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life

Wednesday, March 22, 2017

BOULDER, Colo., March 22, 2017 (GLOBE NEWSWIRE) -- Biodesix®, Inc. announced today the results of a study demonstrating that the use of the VeriStrat® test for patients with non-small cell lung cancer (NSCLC) directly impacts physician treatment decisions in real-world clinical practice. In the study, use of the VeriStrat test resulted in an 89% decrease in ineffective treatments for patients who tested VeriStrat-Poor. A “decision impact” study demonstrates that a test changes the way patients are treated after test results are known. The decision impact study on VeriStrat was published in Current Medical Research and Opinion.  

Flagship Bioscience: Is PD-L1 Harmonization on the Horizon?

Wednesday, March 22, 2017

Dr. Joseph Krueger, Flagship Bioscience’s Chief Scientific Officer, was recently interviewed by BioCentury about cTA™ harmonization or the potential to use one predictive assay to calibrate the output from multiple assays. Dr. Krueger provided insight about how the cTA™ platform could not only calibrate results across multiple assays, but can optimize cutoff points for patient selection. “The potential to more accurately predict which patients will respond to therapy should allow diagnostics using cTA™ to command a better price, and reimbursement, than existing companion diagnostics that require manual assessment by a pathologist.” 

InDevR Launches Next-Generation Software for the Cypher One™ System

Tuesday, March 21, 2017

BOULDER, Colo.--(BUSINESS WIRE)--InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine manufacturing, today announced the global launch of the next-generation Cypher One™ 3.1 software to further enhance the functionality of the Cypher One™ automated hemagglutination (HA) and hemagglutination inhibition (HAI) interpretation instrument. 

ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update

Tuesday, March 21, 2017

Westminster, CO, March 21, 2017 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended December 31, 2016, and provided a business update.  

Funding round brings in $10.5 million for EndoShape

Tuesday, March 21, 2017

EndoShape has raised $10.5 million in a new round of equity financing, according to an SEC filing posted by the company. 

Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber

Monday, March 20, 2017

Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients 

Bioptix sells $2.3 million in private placement

Monday, March 20, 2017

BOULDER — Bioptix Inc. (Nasdaq: BIOP) sold nearly $2.3 million of its securities in a private placement with accredited investors.